Identification of MYC/BCL2 double-expressers lymphomas in diffuse large B cell lymphoma patients and association with their prognostic parameters and survival rates: a single centre experience

Identification of MYC/BCL2 double-expressers lymphomas in diffuse large B cell lymphoma patients and association with their prognostic parameters and survival rates: a single centre experience

Introduction: Diffuse large B cell lymphoma (DLBCL) is a heterogenous disease some of which show co-expression of c-MYC and BCL2 and they are known as double expressers (DE) lymphoma. DE lymphoma has been shown to be associated with aggressive clinical course and poor outcome in comparison to those...

Full description

Bibliographic Details
Main Authors:	Ahmad, Aliza, Abd Ghani, Fauzah, Jaafar, Junalina, Abdullah, Maizaton Atmadini
Format:	Article
Language:	English
Published:	Faculty of Medicine and Health Sciences, Universiti Putra Malaysia 2022
Online Access:	http://psasir.upm.edu.my/id/eprint/99314/1/2022121912262413_MJMHS_0622.pdf

Similar Items

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
by: Sixia Huang, et al.
Published: (2019-07-01)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
by: Yanjie Wang, et al.
Published: (2023-09-01)

The survival impact of combined expression of myc, bcl2 and bcl6 in diffuse large b cell lymphoma patients
by: Adelina BIRCEANU COROBEA, et al.
Published: (2018-06-01)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
by: Weiping Li, et al.
Published: (2019-07-01)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
by: Jonathan Wawire, et al.
Published: (2019-04-01)

Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
by: Ellen D. McPhail, et al.
Published: (2018-11-01)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
by: Yosuke Okada, et al.
Published: (2022-02-01)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
by: Mohammad Barouqa, et al.
Published: (2022-08-01)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
by: Akiko Uchida, et al.
Published: (2019-07-01)

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma
by: Mark Bosch, et al.
Published: (2018-02-01)

High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
by: Alison M. Moore, et al.
Published: (2018-05-01)

Molecular heterogeneity of BCL2/MYC double expressor lymphoma underlies sensitivity to histone deacetylase inhibitor
by: Zi‐Yang Shi, et al.
Published: (2024-06-01)

Cutaneous manifestations as the presenting signs of diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements
by: Gabriela Piñero-Crespo, BS, et al.
Published: (2025-01-01)

Differentiated approach in the treatment of diffuse large B-cell lymphoma according to c-MYC and BCL2 status
by: R. K. Karakulov, et al.
Published: (2022-01-01)

Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
by: Patricia Pérez-Galán, et al.
Published: (2023-02-01)

Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors.
by: Hee Young Na, et al.
Published: (2019-01-01)

DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
by: Chidimma Agatha Akpa, et al.
Published: (2019-01-01)

Zanubrutinib plus R-CHOP improves the treatment effect of newly diagnosed diffuse large B cell lymphoma with double expression of MYC and BCL-2
by: Min Zhang, et al.
Published: (2025-03-01)

Myxoid liposarcoma: a rare soft tissue tumour in the breast
by: Abdullah, Maizaton Atmadini, et al.
Published: (2020)

Evaluation of the Prognostic Importance of c-Myc and Bcl-2 Expressions and the Presence of Epstein-Barr Virus in Classical Hodgkin Lymphoma
by: Aydan KILIÇARSLAN, et al.
Published: (2018-09-01)

Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations
by: Naoto Tomita, et al.
Published: (2009-07-01)

P1216: ZANUBRUTINIB PLUS R-CHOP(RI-CHOP) AS THE TREATMENT FOR DOUBLE EXPRESSION OF MYC/BCL2 IN PATIENTS WITH DIFFUSED LARGE B-CELL LYMPHOMA
by: K. Ren, et al.
Published: (2022-06-01)

Correction: MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Published: (2014-01-01)

Correction: MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.
Published: (2014-01-01)

Correction: MYC Expression in Concert With BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.
by: Li-Xu Yan, et al.
Published: (2018-01-01)

TDT Positive High-Grade Lymphoma with Myc, BCL2 And BCL6 Rearrangements: a Review of Diagnosis and Treatment
by: Aditi Singh, et al.
Published: (2022-02-01)

P1280: TARGETED INHIBITION OF DHODH IS SYNERGISTIC WITH BCL2 BLOCKADE IN LYMPHOMA WITH CONCURRENT MYC AND BCL2 REARRANGEMENT
by: W. Mo, et al.
Published: (2022-06-01)

Redefining the high‐grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report
by: Socorro María Rodríguez‐Pinilla, et al.
Published: (2022-02-01)

Expression of PD-L1 and Its Clinical Significance in MYC/BCL2 Double-expression Large B Cell Lymphoma
by: WANG Ping, et al.
Published: (2020-01-01)

Translating prognostic quantification of c-MYC and BCL2 from tissue microarrays to whole slide images in diffuse large B-cell lymphoma using deep learning
by: Thomas E. Tavolara, et al.
Published: (2024-01-01)

Association of pSTAT3, pSyk with c-Myc, p53, BCL2 proteins expression and survival of patients with diffuse large B-cell lymphoma
by: V. A. Rosin, et al.
Published: (2022-04-01)

Terminal deoxynucleotidyl transferase‐positive high‐grade B‐cell lymphoma with MYC and BCL2 rearrangements transformed from follicular lymphoma
by: Radu Chiriac, et al.
Published: (2024-12-01)

Prevalence and Prognostic Impact of MYC, BCL2, and BCL6 Rearrangements in Large B Cell Lymphoma Patients: A Multicenter Historical Cohort Study from Iran
by: Fatemeh Radmanesh, et al.
Published: (2024-04-01)

P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL
by: F. Morschhauser, et al.
Published: (2022-06-01)

Patched-1 and smoothened, a hedgehog receptor and signal transducer are highly expressed in diffuse large B-cell lymphoma
by: Azman, Siti Nur Lina, et al.
Published: (2017)

BCL2 overexpression in diffuse large B-cell Lymphoma
by: Hajar Masrour, et al.
Published: (2023-01-01)

Case report: Mutation evolution in a patient with TdT positive high grade B cell lymphoma with MYC and BCL2 rearrangements following the treatment of concurrent follicular lymphoma and diffuse large B-cell lymphoma
by: Fen Zhang, et al.
Published: (2024-04-01)

Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
by: Jennifer K. Lue, et al.
Published: (2024-10-01)

Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma
by: Meng-Ke Liu, et al.
Published: (2022-10-01)

Hedgehog signalling molecule, SMO is a poor prognostic marker in bladder cancer
by: Mohd Ariffin, Khairunnisa, et al.
Published: (2021)